Clinical Trial: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285694) titled 'AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)' on Dec. 10.

Brief Summary: This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)

Intervention: BIOLOGICAL: AB-3028

autologous T cell therapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Arsenal Biosciences, Inc.

Disclaimer: Curated by HT Syndication....